Royalty Report: Drugs, Genome, Disease – Collection: 233426

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Genome
  • Disease
  • Therapeutic
  • Delivery
  • DNA
  • cardiac
  • Drug Discovery
  • ribonucleic acid
  • Cancer
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 233426

License Grant
Licensor grants an exclusive license in the Licensed Field of Use to make, use and sell Licensed Product in the Licensed Territory. Such license shall include the right to grant sublicenses.

Licensor grants the right to extend the licenses granted.

License Property
The technology means existing technical data and information that is related to VEGF-2, is provided to Licensee by Licensee, and pertains to the Licensed Patents, Inventions, or the Licensed Field of Use regardless of whether or not such data or information is of a confidential nature.

VEGF-2 means Vascular Endothelial Growth Factor 2.

Gene Therapy shall mean treatment or prevention of a disease, or remedying a gene deficiency of humans by genetic modification of human somatic cells or germ cells (in vivo, in vitro, or ex vivo) with DNA (RNA) for the purpose of expressing a protein or oligo (poly) nucleotide encoded by said DNA (RNA) in a human.

Field of Use
The Licensed Field of Use shall mean the field of Gene Therapy for the treatment of vascular disease.

IPSCIO Record ID: 127805

License Grant
The English Licensor grants a non-exclusive license to make, use, sell, offer for sale or import Licensed Products under the Licensed Patents, with a right to grant sublicenses.
License Property
The certain patents relate to the Factor IX gene.

The licensed products mean viral vector products, including without limitation adenovirus (AV) and adeno-associated virus (AAV) viral vector products, for in vivo human gene therapy.  Specifically excluded are utilization of non-viral vector products, any ex vivo approach based on the administration of living cells, Factor IX protein produced by or from transgenic animals, and any license rights to make, use, offer for sale, sell, or import Factor IX protein.

Field of Use
This agreement is for the human gene therapy industry.

IPSCIO Record ID: 128301

License Grant
For the Licensee products, Licensor grants a non-exclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensor Technology and Licensor Patents to perform research and preclinical development in the Field during the research term using Licensee research genes.

Licensor grants a non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee research genes exercisable during the research term of this Agreement.

Licensor grants an exclusive worldwide license, with the right to grant sublicenses, under Licensor Technology and Patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensors patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 203979

License Grant
Licensor grants a nonexclusive, non-transferable, worldwide license, without the right to grant sublicenses, under Licensors technology and patents to perform research and preclinical development in the field during the research term using Licensee research genes.

Licensor grants non-exclusive, non-transferable options to obtain licenses for up to three (3) Licensee identified Research Genes exercisable during the research term of this Agreement.

With respect to exclusive Licensee products directed to a Licensee research gene for which Licensee has exercised an option Licensor is obligated to grant a license.  Licensor grants to Licensee an exclusive worldwide license under Licensor technology and patents to research, develop, make, have made, use, import, export, offer to sell and sell such exclusive Licensee products in the field.

License Property
The Licensed patents include the Delivery of Exogenous DNA Sequences in a Mammal and the Production of Pharmaceutical-Grade Plasmid DNA.
Field of Use
The field is the intervention, treatment and/or prevention of a disease or disorder in humans by Gene therapy.

IPSCIO Record ID: 233427

License Grant
Licensor grants an exclusive worldwide license (with the right to grant sublicenses) under Licensor Licensed Intellectual Property to research, develop, make, have made, use, import, export, offer to sell and sell Licensed Products in the Field.

Licensor grants a non-exclusive, perpetual, worldwide, sublicensable license to Licensor Improvements and the claims of any Licensor Patent covering such Licensor Improvements, but only to the extent that such claims cover  Licensor Improvements.

License Property
Licensor technology shall mean Cytofectin Delivery Technology, Direct Injection Technology and DNA Process Technology.

Product shall mean any product or part thereof, the manufacture, use or sale of which is covered in whole or in part by a valid claim.

DNA Process Technology shall mean all patentable or unpatentable inventions, discoveries, technology and information of any type whatsoever, including without limitation compositions, methods, processes, confidential information, technical information, knowledge, experience and know-how regarding technologies related to the manufacture and processing of plasmid DNA for human use; in each case, which is owned by or licensed to Licensor on the Effective Date or during the term of this Agreement, all to the extent and only to the extent that Licensor now has or will have during the term of this Agreement the right to grant licenses, immunities or other rights thereunder.

Cytofectin Delivery Technology shall mean all patentable or unpatentable inventions, discoveries, technology and information of any type whatsoever, including without limitation compositions, methods, processes, confidential information, technical information, knowledge, experience and know-how, regarding the use of cytofectins in the delivery of genes into a patient for the treatment or prevention of one or more diseases or conditions; in each case which is owned by or licensed to Licensor on the Effective Date or during the term of this Agreement, all to the extent and only to the extent that Licensor now has or hereafter will have the right to grant licenses, immunities or other rights thereunder.

Direct Injection Technology shall mean all patentable or unpatentable inventions, discoveries, technology and information of any type whatsoever, including without limitation compositions, methods, processes, confidential information, technical information, knowledge, experience and know-how, regarding the direct injection of genes (including plasmid DNA-based delivery technology) into a patient to cause the In Vivo expression of a desired protein, thereby effecting delivery of such protein to a patient for the treatment or prevention of one or more diseases or conditions; in each case which is owned by or licensed to Licensor on the Effective Date or during the term of this Agreement, all to the extent and only to the extent that Licensor now has or will have during the term of this Agreement the right to grant licenses, immunities or other rights thereunder.

Field of Use
Field shall mean the intervention, treatment and/or prevention of a disease or disorder in humans by Gene Therapy.

Licensor's 'naked DNA delivery technology' allows genes to enter the body without being bundled with a virus.

IPSCIO Record ID: 237378

License Grant
The License is granted for the purpose of developing, making, using, selling and otherwise disposing of Product.

The Licensor of England grants to the Licensee the following License
(i)  a non-exclusive sub-license under United States Patent 4,994,371 to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the United States; and,
(ii)  a non-exclusive license under the other Patents to manufacture or have made for it Products and to use, sell or otherwise dispose of, anywhere in the world, Products made in the countries covered by the aforesaid other Patents.

License Property
The patents are for Factor IX Gene Clone.
Field of Use
The field of use is human recombinant Factor IX protein produced from cell culture.  The Field shall exclude any product, therapy, treatment or procedure in which living material is administered or howsoever brought into contact with the recipient of the therapy, treatment or procedure, or any product made for such purpose.  The Field shall also exclude gene therapy or transgenics, or the production by gene therapy, or transgenic animals or transgenic plants, of recombinant Factor IX protein.

IPSCIO Record ID: 260407

License Grant
University grants to Licensee a license under Universitys interest in Patent Rights to make, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods in the Field, within the Territory and during the Term.  The amendment adds the patent information.

The licenses granted in this paragraph is exclusive with respect to the Field only.

License Property
The patent is for the therapy treatment or prevention of cardiovascular disease.
Field of Use
The Field means gene therapy for the treatment or prevention of cardiovascular diseases by the delivery of a gene or a synthetic equivalent (DNA, deoxyribonucleic acid or polydeoxyribonucleotide sequence), in whole or in part or in combination, including those encoding one or more phospholamban genes and/or SERCA-2 (sacroplasmic reticulum calcium ATPase) genes, or their mutants, excepting the involvement of anti-sense RNA (ribonucleic acid or polyribonucleotide sequence) of the phospholamban gene.

IPSCIO Record ID: 233425

License Grant
Licensor grants a nonexclusive, nonsublicensable, nontransferable license under Licensors Patents, for the sole purpose of using, making, having made and selling the Final Products, where such Final Products are sold to Licensor for distribution by Licensor, all in accordance with the terms and conditions of this Agreement.
License Property
The patents are worldwide including but not limited to U.S. Patents  5,661,133 and 6,316,419.

Injection Catheter means the injection catheter known as the Stilettoâ„¢ manufactured by Licensor, including improvements, modifications and replacements thereto.

Product means a plasmid DNA, drug, biologic or other composition comprising VEGF-2.  Product does not include any delivery device, including without limitation the Injection Catheter, a hypodermic needle or stent, or the combination of any such plasmid DNA, drug, biologic or other composition with any such delivery device.

VEGF-2 means the Human Genome Sciences angiogenic agent licensed to and being further developed and modified by the Company, sometimes referred to as Vascular Endothelial Growth Factor 2 plasmid DNA, and any modifications or improvements thereto.

Field of Use
The property is used for treatment of diseases of the heart or peripheral vascular system.

IPSCIO Record ID: 263767

License Grant
Licensor grants to Licensee of the Netherlands a worldwide, exclusive, even as to Licensor, license, with the right to grant Sublicenses, under the Licensed Patent Rights to Exploit GDNF Products in the Licensed Field, and a worldwide, exclusive, even as to Licensor, license, with the right to Sublicenses, under the Licensed Know-How to Exploit GDNF Products in the Licensed Field.
License Property
The licensed property is glial-cell derived neurotrophic factor or GDNF.  The GDNF gene contains the information to produce a protein necessary for the development and survival of nerve cells.

GDNF Product means any Gene Therapy product capable of delivering GDNF or the gene encoding GDNF, or in either case any fragment of GDNF that has Functional Activity.

Field of Use
The Licensed Field means all uses in Gene Therapy.   This agreement specifically mentions the treatment of neurological diseases and other diseases.  The Licensee also plans to combine the GDNF gene with its proprietary adeno-associated virus (AAV) technology to develop gene therapies for a range of CNS applications, such as Huntingtons disease and amyotrophic lateral sclerosis (ALS), with an aim to protect and enhance the function of the affected nerve cells.

Based on the promising early results of GDNF gene therapy product in Parkinson’s disease models, Licensee believe there is an opportunity for a similar approach in other debilitating CNS disorders.

IPSCIO Record ID: 280643

License Grant
The Parties have an agreement to develop technology useful for in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

For the RHOA Target, pursuant to the terms of the Original Agreement, Licensor selected the RHOA Target for the development of RNAi Products directed toward such Target (RHOA Products) and Licensee has an opt-in right for further development and commercialization of RHOA Products.

For the royalty bearing products, the Opt-Out Party/Licensor grants the Continuing Party a license under and to Licensor Technology, that is applicable to such Royalty-Bearing Product, to Develop, Manufacture and Commercialize such Royalty-Bearing Product in the Field in the Territory.

For the Profit-Sharing Products
For Development Licenses, Licensor grants a worldwide license in the Territory, with a right to sublicense to its Affiliates, under Licensor Target Identification and Target Validation RNAi Patent Rights, under Licensors interest in Joint Collaboration Patent Rights and Joint Collaboration Inventions, under Licensor Technology Collaboration Inventions, to Licensor RNAi Technology and under Licensor-Assigned Therapeutic Collaboration Inventions, for the sole purpose of in vitro and/or in vivo target identification and/or target validation research relating to drug discovery and/or development activities of Licensee and/or its Affiliates, including in collaborations with Third Parties in which Licensee and/or its Affiliates has any rights to discoveries made.

For Commercialization Licenses,  Licensor grants a license under and to any and all Licensor Technology to Commercialize Profit-Sharing Products in the Field in the Territory.

The foregoing license shall be Exclusive, Co-exclusive or Non-exclusive, depending upon the time period.

License Property
The developed technology will relate to in vitro and/or in vivo target identification and/or target validation using RNAi and to develop RNAi therapeutic products.

Combination Product means a RHOA Product or an RNAi Therapeutic Product combined with any other clinically active ingredient.

Field of Use
The Field shall mean the treatment and/or prophylaxis of diseases in humans with RNAi Therapeutic Products.

RNA interference, or RNAi, is a naturally occurring mechanism within cells for selectively silencing and regulating specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. RNAi is induced by small, double-stranded RNA molecules. One method to activate RNAi is with chemically synthesized small interfering RNAs, or siRNAs, which are double-stranded RNAs that are targeted to a specific disease-associated gene. The siRNA molecules are used by the natural RNAi machinery in cells to cause highly targeted gene silencing.

Vascular endothelial growth factor (VEGF), originally known as vascular permeability factor (VPF),[1] is a signal protein produced by cells that stimulates the formation of blood vessels.  To be specific, VEGF is a sub-family of growth factors, the platelet-derived growth factor family of cystine-knot growth factors.

IPSCIO Record ID: 248305

License Grant
The English Licensor hereby grants to Licensee and its Affiliates, a non-exclusive, world-wide, sublicensable license under the Licensed Intellectual Property to (i) use, sell, offer for sale, make, have made, import, export and otherwise dispose of Licensed Products in the Licensed Field and (ii) to engage in the research, screening, discovery, development and testing in connection with the Licensed Products in the Licensed Field. The License expressly ex.eludes Licensees and its Affiliates provision of any services to third parties; production and/or sale of kits, diagnostic products or research reagents; products for non-human animal health, agriculture or other industrial applications outside of the Licensed Field.
License Property
Licensed Intellectual Property shall mean US Patent Numbers 8,097,710, 8,258,285, 8,263,569, 8,299,235 and 8,349,607 and US Patent Application Serial Numbers l I/OJ 3,53 l and 12/508,476 and any patents issuing thereupon, including any continuations, divisionals, continuations-in-part, substitutions, reissues, re-examinations, renewals, continued prosecution applications, foreign counterparts and/or extensions of any of the foregoing.

8,097,710 – Gene silencing
8,258,285 – RNA molecules and vectors for gene silencing
8,263,569 – Gene silencing
8,299,235 – RNA molecules and vectors for gene silencing
8,349,607 – Gene silencing

SRM shall mean a short RNA molecule or molecules nominated by Licensee hereof.  Such SRM will be designed to target and modify the expression of a human gene or genes, where such human gene or genes may be any genes selected from across the human genome and may contain a single short RNA molecule or the combination of rwo such short RNA molecules. Such SRM may comprise an SRM series to provide for lead drug candidate and back-up drug candidate (including different formulations, siRNA sequences or siRNA modifications) addressing the same human gene target. Without limitation to the foregoing and for purposes of clarity, an SRM may comprise short RNA molecules designed to target a combination of two (but no more than two) separate gene targets in the human genome.

Field of Use
Licensed Field shall mean the diagnosis, prevention and treatment of disease in humans.

IPSCIO Record ID: 299285

License Grant
University grants an exclusive, world-wide right and license, with the right to grant sublicenses, to make, have made, use and sell joint licensed products.
License Property
The University jointly owns and is a joint proprietor of certain intellectual property relating to the human BRCA-2 breast cancer gene.
Field of Use
The field of use means any and all applications and uses of the BRCA-2 breast cancer gene, including but not limited to all diagnostic and therapeutic applications.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.